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Aberrant expression of DNA repair proteins is associated with poor survival in cancer
patients. We investigated the combined expression of MRE11 and ATM as a predictive
marker of response to radiotherapy in rectal cancer.
Methods
MRE11 and ATM expression were examined in tumor samples from 262 rectal cancer
patients who underwent surgery for rectal cancer, including a sub-cohort of 54 patients who
were treated with neoadjuvant radiotherapy. The relationship between expression of the
two-protein panel and tumor regression grade (TRG) was assessed by Mann–Whitney U
test and receiver operating characteristics area under curve (ROC-AUC) analysis. The
association between expression of the two-protein panel and clinicopathologic variables
and survival was examined by Kaplan-Meier methods and Cox regression analysis.
Results
A high score for two-protein combined expression in the tumor center (TC) was significantly
associated with worse disease-free survival (DFS) (P = 0.035) and overall survival (OS)
(P = 0.003) in the whole cohort, and with DFS (P = 0.028) and OS (P = 0.024) in the neoadju-
vant subgroup (n = 54). In multivariate analysis, the two-protein combination panel (HR =
2.178, 95% CI 1.115–4.256, P = 0.023) and perineural invasion (HR = 2.183, 95% CI 1.222–
3.899, P = 0.008) were significantly associated with DFS. Using ROC-AUC analysis of good
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versus poor histological tumor response among patients treated preoperatively with radio-
therapy, the average ROC-AUC was 0.745 for the combined panel, 0.618 for ATM alone,
and 0.711 for MRE11 alone.
Conclusions
The MRE11/ATM two-protein panel developed in this study may have clinical value as a pre-
dictive marker of tumor response to neoadjuvant radiotherapy, and a prognostic marker for
disease-free and overall survival.
Introduction
Colorectal cancer (CRC) is the third leading cause of cancer related death worldwide [1]. It is
becoming increasingly important to identify prognostic and predictive markers for rectal can-
cer. Surgical resection remains the definitive treatment for CRC. However, rectal cancers are
more challenging to resect than their colonic counterparts due to limited access within the pel-
vic space, as well as close proximity to the mesorectal fascia and pelvic organs. As a result,
patients with rectal cancer consistently suffer from inferior survival outcomes relative to colon
cancer patients [2]. Preoperative radiotherapy aims to downstage the primary tumor, eradicate
microscopic disease, and reduce recurrence rates [3–5]. Unfortunately, tumor response to
radiotherapy varies between individuals, even after adjusting for clinico-histopathological vari-
ables. Tumor down staging following preoperative radiotherapy occurs in approximately 60%
of patients, but only 10–30% will display a complete response [6] [7]. The availability of a pre-
dictive marker of radiation sensitivity would enable selective administration of therapy to
those most likely to respond.
Radiotherapy instigates cell death by causing ionizing radiation-induced double-strand
breaks (DSBs) in the DNA, which initiates the DNA damage response (DDR) leading to cell
cycle arrest and repair of the damage or, if repair is unsuccessful, cell death. Two early, integral
components in this pathway are ataxia telangiectasia mutated (ATM), a serine/threonine pro-
tein kinase belonging to the phosphatidylinositol 3-kinase-like (PIKK) family [8] and the
MRN complex, a trimer of MRE11 (meiotic recombination 11), RAD50 and NBS1 molecules.
The latter complex binds to the DSBs and generates regions of single stranded DNA with its
nuclease activity, which then recruits ATM to the site of genetic damage. ATM in turn affects
cell cycle arrest [9].
As might be expected from the critical role of DNA repair in maintaining genomic integ-
rity, many cancers, including CRC, exhibit deficiencies in the DNA damage response and
DNA repair pathways. Specifically, MRE11 deficiency is associated with improved overall sur-
vival (OS) and long-term disease-free survival (DFS) in patients with stage III colon cancer
independent of treatment [10], suggesting that MRE11 status has value as a prognostic marker
in CRC.
We hypothesized that acquired deficiencies in ATM and/or MRE11 would lead to a dys-
functional repair mechanism and an inability to restore genomic stability, resulting in
increased tumor cell death following radiotherapy. At least in the relatively small, but well
characterized subgroup of microsatellite unstable CRCs with deficiencies in DNA mismatch
repair (MMR) proteins, the accumulation of errors during replication and recombination [11]
presents a mechanism for inactivation of ATM and MRE11 through function-ablating muta-
tions. As a corollary, we proposed that ATM and MRE11 might be used as a predictive marker
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of radiosensitivity in rectal cancer patients, which would correlate with improved patient
outcomes.
Thus, we investigated the value of expressions of MRE11, ATM and combined MRE11/
ATM as a predictive marker of response to radiotherapy in rectal cancer and as a prognostic
marker in general, and performed univariate and multivariate analyses on various clinicopath-
ologic factors according to their expression levels.
Materials and Methods
Patient samples
This study received ethics approval from the South Western Sydney Local Health District
(SWSLHD) Human Research Ethics Committee (reference number HREC/12/LPOOL/102).
Specifically, the research was conducted under the Protocol numbers X01-0138 and X03-0291
for the IHC assessment in paraffin embedded rectal cancer tissues and retrospective survival
analyses. The ethics committee waived the need for direct consent for patients as samples and
clinical data were all de-identified before access.
Specimens were obtained from 262 rectal cancer patients who underwent surgery in the
SWLHD from 2000–2011. Clinicohistopathological data were collated and are summarized in
Table 1. Standard radiotherapy treatments were at a dose of 25 Gy in 5 treatment fractions
when performed alone or at 50.4 Gy in 28 treatment fractions when combined with 5 fluoro-
uracil based chemotherapy. Short-term response to radiotherapy was measured by tumor
regression grade (TRG) per the 7th edition of the American Joint Committee on Cancer
(AJCC) manual [12] on a scale of 0 to 3: 0, complete response with no viable malignant cells; 1,
moderate response with single or small groups of malignant cells; 2, minimal response with
residual malignancy outgrown by fibrosis; 3, poor response with extensive residual malig-
nancy. TRG 0, 1 and 2 were categorized as responders and TRG 3 as non-responders. Long-
term response to radiotherapy was measured by survival outcomes including DFS and OS.
Specimens obtained from primary surgery for rectal or rectosigmoid cancers were obtained
from the South-Western Area Pathology database, Australia. Surgery consisted of total mesor-
ectal excision, with anterior or abdominoperineal resection. Variables of interest included age,
gender, pathological TNM stage, grade, vascular invasion, perineural invasion, tumor-infiltrat-
ing lymphocytes, and treatment. Outcomes of interest were DFS, OS and histologic TRG in
the resected bowel for cases treated with neoadjuvant chemoradiation. DFS was defined as the
time from diagnosis to first recurrence, if any. OS was defined as the time from diagnosis to
last follow-up or death. Follow-up consisted of regular clinic visits, colonoscopy, blood tests,
and imaging at the discretion of the treating specialist.
Sample preparation and tissue microarrays
For each patient, donor blocks of archived paraffin-embedded tissue were retrieved and two
1mm diameter cores were obtained from each sampling site: tumor center (TC), tumor
periphery at invasive edge (TP), normal mucosa close/adjacent to tumor, normal mucosa well
away from tumor, usually at the resection end margin, and from involved lymph nodes (LN).
These were transferred into pre-drilled wells in a tissue microarray block and mounted on
slides for immunohistochemistry.
Immunohistochemistry
Slides were deparaffinized in xylene and rehydrated in graded ethanol. Antigen retrieval was
performed with Envision™ FLEX Target Retrieval Solution, pH 9.0, in a 98˚C water bath for 10
Protein Biomarkers in Rectal Cancer
PLOS ONE | DOI:10.1371/journal.pone.0167675 December 8, 2016 3 / 15
minutes for ATM and 45 minutes for MRE11. This was followed by incubation for 5 minutes
at room temperature with Envision™ FLEX Peroxidase-Blocking Reagent to block endogenous
peroxidases. Slides were incubated with monoclonal anti-ATM primary antibody [2C1 (1A1)]
(1:800 dilution, Abcam, Cambridge, UK) for 30 minutes at room temperature and with anti-
MRE11 primary monoclonal mouse antibody (1:600 dilution, ab214, Abcam). After washing
with TBST buffer, slides were incubated for 15 minutes with Dako mouse linker, rinsed, and
Table 1. Patient characteristics.
All Patients (%) Preoperative Radiotherapy Group
Total, n 262 54
Age median 71 67
Gender
Male 174 (66.4) 38 (70.4)
Female 88 (33.6) 16 (29.6)
Tumor stage
T1-2 86/257 (33.5) 17/54 (31.5)
T3-4 171/257 (66.5) 37/54 (68.5)
Node stage
N0 137/256 (53.5) 28/54 (51.9)
N1-2 118/256 (46.5) 26/54 (48.1)
Metastasis stage
M0 220/237 (92.8) 52/53 (98.1)
M1 17/237 (7.2) 1/53 (1.9)
Grade
1–2 242/262 (92.4) 50/54 (92.6)
3 20/262 (7.6) 4/54 (7.4)
Vascular invasion
Absent 198/260 (76.2) 46/54 (85.2)
Present 62/260 (23.8) 8/54 (14.8)
Perineural invasion
Absent 218/260 (83.8) 41/54 (75.9)
Present 42/260 (16.2) 13/54 (24.1)
Radiotherapy
Total 76/245 (31.0) -
Neoadjuvant 54/76 (71.1) -
Adjuvant 22/76 (28.9) 0/54 (0)
Recurrence
Absent 129/211 (61.1) 48/54 (88.9)
Present 82/211 (38.9)* 6/54 (11.1)†
Tumor regression grade
0–2 (good response) - 9/54 (16.7)
3 (poor response) - 45/54 (83.3)
Chemotherapy
Total 98/219 (44.7) 38/54 (70.4)
Neoadjuvant 38/98 (38.8) 31/38 (81.6)
Adjuvant 60/98 (61.2) 7/38 (18.4)
* Local and distant recurrence,
† Local recurrence only.
doi:10.1371/journal.pone.0167675.t001
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incubated for 30 minutes with anti-mouse secondary antibody. The peroxidase substrate used
was a mixture of Envision™ FLEX DAB+Chromogen DM827 and Envision™ FLEX Substrate
Buffer DM823 (DAKO). Slides were counterstained with hematoxylin, washed with cold
water, and then dipped 10 times in Scott Bluing solution. Slides were immediately rinsed with
cold water before dehydration and mounting.
Immunohistochemical scoring
ATM expression was initially scored as the product of percentage and intensity of staining
based on Angele et al [13]. The percentage of positive staining was scored as: 1,<25%; 2, 25%–
50%; 3, 50%–75%; or 4,>75%. The intensity of staining was graded as: null, 0; low, 1; moderate,
3; or high, 5. The two scores were multiplied to create a composite score between 0 and 20
and analyzed against clinicohistopathological and clinical outcome data. The percentage of
MRE11-positive cells and staining intensity were also scored using the methods published pre-
viously [14]. Intensity was graded as: negative, 0; weak, 1; moderate, 2; or strong, 3. The per-
centage of positive cells was graded as: 0,<5%; 1, 5%–25%; 2, 26%–50%; 3, 51%–75%; and 4,
>75%. These two measures were multiplied to give weighted scores ranging from 0–12. To
combine the two proteins as a biomarker panel, all cases were categorized into either a low
expression group (score range: 0–5) and a high expression group (score range: 6–32).
Statistical analysis
Statistical analysis was performed with SPSS Statistics for Windows 20.0 (Chicago, IL, USA).
ATM expression was compared with clinicohistopathological data using Pearson’s χ2 test, and
the association of MRE11 expression with clinicohistopathological variables was assessed by
Fisher’s exact test. ATM and MRE11 expression levels were compared and combined by binary
logistic regression as described previously [15]. Survival analyses were performed in the overall
cohort and separately in patients who received preoperative radiotherapy. Univariate and mul-
tivariate analyses were performed using Kaplan Meir curves and Cox’s proportional hazards
survival modeling for the combined two-marker expression levels from cancer core and
periphery samples. Covariates were sex, age, TNM stage, grade, vascular invasion, perineural
invasion, treatment with chemotherapy and radiotherapy, and TRG. Univariate analysis by the
Mann–Whitney U test was also used to assess associations between the single and combined
two-marker expression levels in rectal tumor tissue with TRG, which was further characterized




Patient characteristics are detailed in Table 1. The patients’ median age was 71 years (range:
35–100 years). Among 262 patients, 174 (66.4%) were male and 88 (33.6%) were female. Sev-
enty six of 245 (31.0%) patients were treated with radiotherapy, of which 54 of 76 (71.1%)
received preoperative therapy. Disease-free and OS data were available for 211 and 248
patients, respectively. Patients were followed for a median period of 3.2 years (range: 0−12.6
years). Local recurrence of disease occurred in 82/211 (38.9%) patients. The median time to
recurrence was 2.12 years. At the time of the study, 141/248 (56.9%) patients were alive. The
median time to death was 2.5 years following surgery (range: 0−11.1 years). Among patients
who received preoperative radiotherapy, local recurrence occurred in 6/54 (11.1%) patients
and median time to recurrence was 2.61 years (range: 0.75−4.29 years). All six patients (100%)
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had died by the end of this study. The median time to death following recurrence was 3.81
years (range: 0.6−10.9 years).
Establishment of the combined two-protein biomarker panel
ATM and MRE11 protein expression levels in the TC were tested in a forward and reverse
binary logistic regression analysis using a data set of immunohistochemical scoring derived
from 257 tumor samples and 255 normal tissues. The final biomarker model gave an average
receiver operator characteristic area under the curve (ROC-AUC) value of 0.849 for the combi-
nation of the two proteins. Similarly, ATM and MRE11 protein expression levels in the TP
(tumor, n = 258; normal, n = 255) were also tested, and the model gave an average ROC-AUC
value of 0.837. The sensitivity and specificity of the two-protein combined panel were 80.9%
and 70.3% for TC and 61.6% and 48.8% for TP, respectively, and overall accuracy was 75.6%
(TC) and 55.2% (TP) (S1 Table).
Relationship between ATM and MRE11 protein expression and
clinicopathological features
We examined the association of ATM and MRE11 expression levels with clinicopathological
variables independently. ATM protein expression was analyzed in 259 central and 260 periph-
eral tumor cores. Samples from TC displayed high expression in 84% and low expression in
16%. Samples from TP showed high expression in 79% and low expression in 21%. There was
a higher level of ATM expression in TC (mean (M) = 6.84) compared to TP (M = 5.28). This
difference was found to be significant (P<0.001).
ATM expression was seen in 199/228 (87%) of adjacent normal mucosa and 204/250 (82%)
of distal normal mucosa. ATM expression was higher in normal mucosa taken near the tumor
(M = 6.43) compared to samples taken away from the tumor (M = 4.25). Again, this finding
was statistically significant (P<0.001). ATM expression in both TC and TP were significantly
higher than in distal normal mucosa (P<0.001 and P = 0.005 respectively), but not signifi-
cantly different to that in the adjacent normal mucosa.
Low ATM expression in the TP was associated with older age (P = 0.013) and higher histo-
logic grade (P = 0.044).(S2 Table). There was no correlation with sex, TNM category, vascular
invasion, or perineural invasion. Expression of ATM in TC was not associated with any clini-
cohistopathological variables.
MRE11 expression in the TC was high in 45% of cases and low in 52%. Expression in the
TP was high in 56% and low in 44%. Mean weighted scores were significantly different
between TC and TP (5.5 versus 5.8, P<0.05 by paired t-test). The mean MRE11 score was 4.2
for both adjacent and distal normal tissue, which was significantly different from the score for
both the TC and TP (P<0.001). There were no significant associations between MRE11 score
in the TC or TP and clinicopathologic characteristics (S3 Table).
Association between combined expression levels with pathological
variables and prognosis
Next, we examined a possible association of clinicopathological characteristics and survival
outcomes with the ATM/MRE11 two-protein combined panel. Fig 1A shows representative
immunohistochemical staining of high and low/absent ATM and MRE11 expression in rectal
cancer tissues. Results from the combined marker analysis differed from our initial single bio-
marker studies of ATM and MRE11 alone, in that a high combined expression of ATM and
MRE11 was significantly associated with a number of clinicopathological variables. These
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Fig 1. Association between combined protein expression levels of ATM and MRE11 in rectal cancer
tissues and survival. (A) Representative immunohistochemical staining of ATM and MRE11 in rectal cancer
tissues. Bar = 200 μm. Staining for each protein was scored as high or low, as described in the Materials and
Methods. (B) Overall survival according to combined protein expression levels of ATM and MRE11 was
determined by Kaplan−Meier survival analyses and compared using the log-rank test. Patients with high
combined protein expression levels of ATM and MRE11 in the TC (green line) showed significantly worse OS
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included neoadjuvant status (P = 0.001 for TC), TRG (P = 0.03 for TC, P = 0.011 for TP), age
(P = 0.02 for TP), and nodal stage (P = 0.042 for TP) (Table 2).
In Kaplan Meier survival analysis, a high score for the two-protein combined expression in
the TC was significantly associated with worse OS (P = 0.003) and DFS (P = 0.035) (Fig 1B and
1C). However, no significant survival difference was seen between high and low groups for
expression in the TP (OS, P = 0.208 and DFS, P = 0.748; Fig 1D and 1E, respectively). In uni-
variate Cox regression analysis, a high two-protein combined status in the TC (combined TC
high versus low: HR = 1.944, 95% CI 0.037–3.645, P = 0.038) was significantly associated with
reduced DFS (Table 3). In multivariate Cox analysis (adjusted for combined expression of
ATM and MRE11, and perineural invasion), the two-protein combination panel (HR = 2.178,
95% CI 1.115–4.256, P = 0.023) as well as perineural invasion (HR = 2.183, 95% CI 1.222–
3.899, P = 0.008) remained significantly associated with DFS (Table 3).
than those with low expression (blue line; P = 0.003). (C) Similarly, patients with high expression levels in the
TC (green line) exhibited worse disease-free survival than those with low expression (blue line; P = 0.035). (D
and E) When measured in the TP, no significant survival difference was seen between the high- and low-
expression groups for overall survival (P = 0.208) or disease-free survival (P = 0.748).
doi:10.1371/journal.pone.0167675.g001
Table 2. Associations between the combined expression of ATM and MRE11 in the tumor center and tumor periphery and clinicohistopathological
data.
Combined TC Combine TP
Low (%) High (%) P value Low (%) High (%) P value
Sex Male 62.5 67.3 0.562 65.3 66.8 0.381
Female 37.5 32.7 34.7 33.2
Age 70 43.8 46.3 0.747 42.9 46.0 0.020
>70 56.2 53.7 57.1 54.0
Tumor stage T1–2 50.0 29.5 0.496 38.3 31.9 0.877
T3–4 50.0 70.5 61.7 68.1
Node stage Negative 60.0 52.4 0.840 44.7 55.8 0.042
Positive 40.0 47.6 55.3 44.2
Metastasis stage M0 97.8 91.6 0.282 100 91.1 0.252
M1 2.2 8.4 0 8.9
Grade 1–2 93.8 92.1 0.508 89.8 92.9 0.131
3 6.2 7.9 10.2 7.1
Vascular invasion Absent 82.6 74.6 0.231 77.1 75.6 0.380
Present 17.4 25.4 22.9 24.4
Perineural invasion Absent 84.8 83.6 0.928 85.4 83.3 0.500
Present 15.2 16.4 14.6 16.7
Adjuvant therapy No 70.0 69.5 0.483 65.0 70.9 0.55
Yes 30.0 30.5 35.0 29.1
Neoadjuvant therapy No 65.2 81.1 0.001 71.7 79.9 0.64
Yes 34.8 18.9 28.3 20.1
Tumor regression grade 0–2 31.6 8.0 0.030 33.3 6.0 0.011
3 68.4 92.0 66.7 94.0
Abbreviations: TC, Tumor center; TP, Tumor periphery
doi:10.1371/journal.pone.0167675.t002
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Prognostic implications of two-protein combined panel in LN-positive
and neoadjuvant radiotherapy subgroups
As noted above, DFS of rectal cancer patients with overexpression of the two-protein com-
bined panel was significantly worse than that of patients with lower expression. When patients
were grouped according to LN involvement, high expression of the two-protein combined
panel was associated with decreased DFS in patients with LN-positive tumors (P = 0.029; Fig
2B) but not in those with LN-negative tumors (P = 0.480; Fig 2A). By multivariate Cox analy-
sis, expression of the two-protein combined panel in TC in the LN positive subgroup signifi-
cantly correlated with DFS (HR = 3.474, 95% CI 1.054–11.451, P = 0.041) (Table 3).
The OS estimates in the subgroup with neo-adjuvant radiotherapy are shown in Fig 2C,
demonstrating that higher combined expression level was significantly associated with worse
OS (P = 0.024). Similarly, DFS of radiotherapied patients with overexpression of two-protein
combined panel was significantly worse than that of patients with lower expression (Fig 2D,
P = 0.028), implicating that the MRE11/ATM two-protein panel has specific potential as a pre-
dictive marker of tumour response to radiotherapy.
Table 3. Cox regression analyses of combined TC expression level with clinicopathologic variables and DFS.
Univariate Multivariate
n (%) HR 95% CI P Value HR 95% P Value
Combined TC
High 81.3 1.944 1.037–3.645 0.038 2.178 1.115–4.256 0.023
Low 18.7
Tumor stage
T1–2 33.5 1.504 0.899–2.517 0.12
T3–4 66.5
Node stage
Negative 53.5 1.132 0.703–1.825 0.609
Positive 46.5
Grade
1–2 92.4 1.617 0.699–3.739 0.261
3 7.6
Vascular invasion
Absent 76.2 1.164 0.637–2.129 0.662
Present 23.8
Perineural invasion
Absent 83.8 2.334 1.310–4.157 0.004 2.183 1.222–3.899 0.008
Present 16.2
Adjuvant therapy
No 91.0 0.605 0.343–1.067 0.082
Yes 9.0
Neoadjuvant therapy
No 77.7 1.088 0.630–1.878 0.762
Yes 22.3
LN-negative† combined TC 53.5 1.343 0.591–3.052 0.481
LN-positive† combined TC 46.5 3.474 1.054–11.451 0.041
Abbreviations: HR, hazard ratio; CI, confidence intervals; TC, tumor center; LN, lymph node;
†denotes interaction
doi:10.1371/journal.pone.0167675.t003
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ATM and MRE expression in relation to TRG
To investigate the relationship between TRG and tissue levels of ATM, MRE11, and the two-
protein combined panel, univariate analysis was carried out using the Mann−Whiney U test
(SPSS). A significant association was seen between increasing TRG and TC expression of the
MRE11 protein (P = 0.015, Fig 3B) and of the combined two-protein panel (P = 0.011, Fig 3C).
Fig 2. Kaplan-Meier survival analysis. (A) and (B) respectively show survival curves of high (green line) and low (blue line)
ATM/MRE11 two-protein expression groups in lymph node (LN) negative and LN positive rectal cancers. These show the
effect of LN status on the association between expression levels and disease-free survival (DFS). (C) and (D) respectively
show overall survival (OS) and DFS survival curves of 54 patients who received preoperative radiotherapy in terms of high
(green line) and low (blue line) two protein expression groups. Worse OS (P = 0.024) and DFS (P = 0.028) were seen with high
expression.
doi:10.1371/journal.pone.0167675.g002
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Fig 3. ROC-AUC analysis of ATM, MRE11, and combined protein panel expressions with tumour
regression grade (TRG). (A−C) Box plots show levels of ATM, MRE11, and their combined expression in the
TC categorized by TRG as 0–2 (good response) or 3 (poor response). The association between protein
expression with TRG was examined by Mann−Whitney U test (ATM, P = 0.27; MRE11, P = 0.015; and
combined proteins, P = 0.011). (D) Receiver operating characteristic (ROC) curve analysis comparing the
performance of ATM and MRE11 alone with the combined 2-protein panel.
doi:10.1371/journal.pone.0167675.g003
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The discriminatory power of each protein biomarker and their combination in TC was charac-
terized using a ROC-AUC analysis of good response (TRG 0–2) versus poor response (TRG3)
groups. The average ROC-AUC was 0.745 for the combined panel of two proteins, compared
with 0.618 for ATM and 0.711 for MRE11 proteins (Fig 3D). These results suggest that the
combined two protein biomarkers provide good discrimination between good and poor
tumor responses after radiotherapy.
Discussion
Despite intensive research into biomarkers and prognostic factors for CRC, little is known
about the factors influencing the survival of patients with rectal cancer. Although there is over-
lap with the treatment of colon cancer in the metastatic setting, rectal cancers in the locoregio-
nal setting are managed differently from colon cancers [16]. The 1997 Swedish Cancer Trial of
patients with resectable rectal cancer showed that preoperative radiotherapy improved both
short-term and long-term local recurrence rates and OS compared with surgery alone [17]
[18], although the authors noted that the use of radiotherapy was associated with side effects
[17]. Since then, the benefits of preoperative radiotherapy or chemoradiotherapy have been
corroborated in several meta-analyses [3,4,19,20].
At the individual level however, there can be significant variation in the degree of initial
tumour response to radiotherapy. In this context, the TRG score provides an indicator of the
regressive response of a tumor to cytotoxic treatment such as radiotherapy. The AJCC Staging
Manual (7th ed.) recommends consideration of the TRG independent of the TNM system. The
TRG provides important prognostic information because complete or subtotal tumor regres-
sion is widely recognized to be associated with better patient outcomes [3,6,19]. Unfortunately,
the majority of patients show no response or only a partial response to neoadjuvant therapy.
For example, none of the patients in our study showed a complete TRG response; 82.4%
showed a poor response and 17.6% showed a minimal to moderate response. However, a
meta-analysis performed by Lee et al indicated that even partial tumor regression after preop-
erative chemoradiotherapy improves DFS, and should be considered as a favorable prognostic
factor [21].
Given the dismal prognosis of patients with rectal cancer and the variation in response to
radiotherapy, a reliable biomarker of intrinsic tumor radiosensitivity would improve assess-
ment of prognosis and aid in making proper treatment decisions. It would help to avoid
adverse side effects of neoadjuvant radiotherapy in patients who are unlikely to benefit, and at
the same time identify those who may subsequently benefit from intensification of therapy.
Although several biomarkers have been studied as predictors of radiotherapy response [22],
the most extensively studied are MRE11 and the radiosensitivity index (RSI), a multigene
expression model of tumor radiosensitivity, which was developed to predict treatment out-
comes independent of disease site [23]. However, to date, these biomarkers have not been vali-
dated in randomized trials, and their clinical value remains unclear. For instance, Sheridan
and colleagues [24] found no correlation between MRE11 expression and survival or radiosen-
sitivity in patients with CRC, albeit with the limitations of a small sample size and short fol-
low-up period. In our study, MRE11 expression alone was not significantly associated with
any clinicopathologic characteristics, while in terms of ATM only low expression in TP was
associated with older age and higher histologic grade, whereas ATM expression in TC was not
associated with any clinicopathologic characteristics.
Based on the hypothesis that both ATM and MRE11 are integral to the detection of DNA
damage and subsequent intracellular signalling following radiotherapy, and hence their defi-
ciency would equate to increased radiosensitivity, we established a two-marker panel of ATM
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and MRE11 expression by binary regression analysis of tumor samples and normal tissues.
Subsequent analyses showed greater association with general clinicopathologic parameters
than either marker alone, as well as yielding a ROC-AUC value of 0.745 in predicting poor his-
tological tumour regression (i.e. TRG 3) following radiotherapy. The latter was superior to
using ATM (0.618) or MRE11 (0.711) alone. Furthermore, in both the neoadjuvant radiother-
apy sub-cohort and the overall cohort, the combined ATM/MRE11 expression levels corre-
lated with clinical survival outcomes. Thus these markers, when used together, related to both
early (histological tumour regression) and late (clinical survival) response to neoadjuvant ther-
apy in rectal cancers. These findings support our hypothesis and are also consistent with the
fact that inhibitors of ATM and the MRN complex have been shown to have potential as radio-
sensitizing agents [25].
It is evident in our results that there are differences in the expression levels and their associ-
ation with clinicopathological variables and survival outcomes when comparing the results
from the centre versus periphery of the tumour mass. Effects of the sampling site on associa-
tions with tumor protein expression have been noted previously. For example, in an evaluation
of biomarkers in ovarian cancer, Permuth-Wey et al reported sampling variability in protein
expression analysis using tissue microarrays [26]. The authors concluded that, for ovarian can-
cer at least, more reliable data were obtained from the TP than from the TC. This was attrib-
uted to optimal exposure to fixatives at the periphery of the processed tissues, although the
effect of tumor heterogeneity on sampling variation should also be considered. For instance,
TCs in general are more liable to hypoxia and necrosis compared to TP, and ischaemic injury
may be another potential source for the biological differences seen within the same tumour.
On a final note, the role of LN status in predicting outcomes is intriguing, and hints at the
complexity of using biomarkers to predict patient outcomes. Among patients with LN-nega-
tive tumors, there was no significant difference in survival between patients with high vs. low
two-protein combined panel score in TC. In contrast, in patients with LN-positive tumors,
high two-protein combined panel scores in TC were significantly associated with worse sur-
vival. This suggests that the combined expression of ATM and MRE11 may be associated with
LN involvement in relation to patient survival.
Conclusions
Overall, our findings suggest that the optimal management of rectal cancer requires tailored
treatment based on biomarker expression such as the two-protein MRE11/ATM panel
described here, as well as clinicopathologic characteristics. Further elucidation of biomarkers
that predict the response to radiotherapy and/or chemoradiotherapy will constitute important
progress toward the individualized treatment of patients with rectal cancer. In this regard, we
are continuing studies on ATM and MRE11 in independent datasets focusing on pre-treat-
ment specimens in comparison to post-treatment specimens.
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